Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07801222 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma

Name: A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma — clinical trial record (NCT07801222)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorSOTIO Biotech a.s.

Started2026-09-30

View on ClinicalTrials.gov ↗

SOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT106, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.

Trial Details

NCT Number	NCT07801222
Lead Sponsor	SOTIO Biotech a.s.
Conditions	Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced
Enrollment	70 participants
Start Date	2026-09-30
Primary Completion	2029-01-19 (estimated)
Study Completion	2030-05-21 (estimated)
Updated on ClinicalTrials.gov	2026-09-03